Evidence map›Paper›PMID 32689968›Full record

ArticleBMC cancer2020

Three-year outcome after transanal versus laparoscopic total mesorectal excision in locally advanced rectal cancer: a multicenter comparative analysis.

F B de Lacy, S X Roodbeen, J Ríos, J van Laarhoven, A Otero-Piñeiro, R Bravo, T Visser, R van Poppel, S Valverde, R Hompes and 5 more

Open access · goldAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 4 pooled it
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

F B de LacyDepartment of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic, IDIBAPS, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Centro Esther Koplowitz, and Cellex Biomedical Research Center, Barcelona, Catalonia, Spain. borjalacy@gmail.com.ORCID http://orcid.org/0000-0002-1485-7668
S X RoodbeenDepartment of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
J RíosMedical Statistics Core Facility, August Pi and Sunyer Biomedical Research Institute (IDIBAPS); Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Villarroel 170, 08036, Barcelona, Catalonia, Spain.
J van LaarhovenDepartment of General Surgery, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, The Netherlands.
A Otero-PiñeiroDepartment of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic, IDIBAPS, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Centro Esther Koplowitz, and Cellex Biomedical Research Center, Barcelona, Catalonia, Spain.
R BravoDepartment of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic, IDIBAPS, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Centro Esther Koplowitz, and Cellex Biomedical Research Center, Barcelona, Catalonia, Spain.
T VisserDepartment of Surgery, Gelderse Vallei Hospital, Ede, The Netherlands.
R van PoppelDepartment of Surgery, Gelderse Vallei Hospital, Ede, The Netherlands.
S ValverdeDepartment of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic, IDIBAPS, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Centro Esther Koplowitz, and Cellex Biomedical Research Center, Barcelona, Catalonia, Spain.
R HompesDepartment of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
C SietsesDepartment of Surgery, Gelderse Vallei Hospital, Ede, The Netherlands.
A CastellsDepartment of Gastroenterology, Institute of Digestive and Metabolic Diseases, Hospital Clinic, IDIBAPS, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.
W A BemelmanDepartment of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
P J TanisDepartment of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
A M LacyDepartment of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic, IDIBAPS, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Centro Esther Koplowitz, and Cellex Biomedical Research Center, Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESAmsterdam University Medical Centers · NLZiekenhuis Gelderse Vallei · NLJeroen Bosch Ziekenhuis · NLUniversitat Autònoma de Barcelona · ES

Funding

Hospital Clinic Barcelona 25_delacyoliverb_250709_cgicm_pfr2018
6 · The paper itself

Abstract

backgroundFor patients with mid and distal rectal cancer, robust evidence on long-term outcome and causal treatment effects of transanal total mesorectal excision (TaTME) is lacking. This multicentre retrospective cohort study aimed to assess whether TaTME reduces locoregional recurrence rate compared to laparoscopic total mesorectal excision (LapTME).

methodsConsecutive patients with rectal cancer within 12 cm from the anal verge and clinical stage II-III were selected from three institutional databases. Outcome after TaTME (Nov 2011 - Feb 2018) was compared to a historical cohort of patients treated with LapTME (Jan 2000 - Feb 2018) using the inverse probability of treatment weights method. The primary endpoint was three-year locoregional recurrence.

resultsA total of 710 patients were analysed, 344 in the TaTME group and 366 in the LapTME group. At 3 years, cumulative locoregional recurrence rates were 3.6% (95% CI, 1.1-6.1) in the TaTME group and 9.6% (95% CI, 6.5-12.7) in the LapTME group (HR = 0.4; 95% CI, 0.23-0.69; p = 0.001). Three-year cumulative disease-free survival rates were 74.3% (95% CI, 68.8-79.8) and 68.6% (95% CI, 63.7-73.5) (HR = 0.82; 95% CI, 0.65-1.02; p = 0.078) and three-year overall survival 87.2% (95% CI, 82.7-91.7) and 82.2% (95% CI, 78.0-86.2) (HR = 0.74; 95% CI, 0.53-1.03; p = 0.077), respectively. In patients who underwent sphincter preservation procedures, TaTME was associated with a significantly better disease-free survival (HR = 0.78; 95% CI, 0.62-0.98; p = 0.033).

conclusionsThese findings suggest that TaTME may improve locoregional recurrence and disease-free survival rates among patients with mid and distal locally advanced rectal cancer.

Indexed as

AdenocarcinomaAgedDisease-Free SurvivalFemaleHumansLaparoscopyMaleNeoplasm Recurrence, LocalOrgan Sparing TreatmentsRectal NeoplasmsRectumRetrospective StudiesSurvival RateTime FactorsTransanal Endoscopic SurgeryTreatment OutcomeLocoregional recurrenceRectal cancerTaTMETotal mesorectal excision

Identifiers

PMID32689968
PMCPMC7372845
OpenAlexW3045424085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.